Zealand Pharma slides after obesity drug data
BUZZ-Zealand Pharma slides after obesity drug data ** Shares in Zealand Pharma ZELA.CO fall around 4%, analysts say experimental obesity drug petrilintide developed with Roche ROPC.S underwhelmed on blood sugar control data
** Wider healthcare sector also down, STOXX healthcare index .SXDP -1.8% at 1107 GMT
** Brokerage William Blair says that while tolerability of the drug was encouraging, the weight loss and reduction in average blood sugar levels "disappointed"
** KBC Securities says the drug will unlikely emerge as "the best-in-class amylin"
** It cuts its peak-sales estimates for petrelintide to $3 billion from $7 billion, citing also heating up pricing pressure in obesity drugs
** It also cuts its rating on the stock to "hold", lowering PT by 42% to 290 Danish crowns
(Reporting by Vera Dvorakova)
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey